...
首页> 外文期刊>Breast Cancer Research >Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death
【24h】

Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death

机译:靶向干扰素反应基因可使抗芳香化酶抑制剂的乳腺癌细胞对雌激素诱导的细胞死亡敏感

获取原文

摘要

IntroductionEstrogen deprivation using aromatase inhibitors (AIs) is currently the standard of care for postmenopausal women with hormone receptor-positive breast cancer. Unfortunately, the majority of patients treated with AIs eventually develop resistance, inevitably resulting in patient relapse and, ultimately, death. The mechanism by which resistance occurs is still not completely known, however, recent studies suggest that impaired/defective interferon signaling might play a role. In the present study, we assessed the functional role of IFITM1 and PLSCR1; two well-known interferon response genes in AI resistance.MethodsReal-time PCR and Western blot analyses were used to assess mRNA and protein levels of IFITM1, PLSCR1, STAT1, STAT2, and IRF-7 in AI-resistant MCF-7:5C breast cancer cells and AI-sensitive MCF-7 and T47D cells. Immunohistochemistry (IHC) staining was performed on tissue microarrays consisting of normal breast tissues, primary breast tumors, and AI-resistant recurrence tumors. Enzyme-linked immunosorbent assay was used to quantitate intracellular IFNα level. Neutralizing antibody was used to block type 1 interferon receptor IFNAR1 signaling. Small interference RNA (siRNA) was used to knockdown IFITM1, PLSCR1, STAT1, STAT2, IRF-7, and IFNα expression.ResultsWe found that IFITM1 and PLSCR1 were constitutively overexpressed in AI-resistant MCF-7:5C breast cancer cells and AI-resistant tumors and that siRNA knockdown of IFITM1 significantly inhibited the ability of the resistant cells to proliferate, migrate, and invade. Interestingly, suppression of IFITM1 significantly enhanced estradiol-induced cell death in AI-resistant MCF-7:5C cells and markedly increased expression of p21, Bax, and Noxa in these cells. Significantly elevated level of IFNα was detected in AI-resistant MCF-7:5C cells compared to parental MCF-7 cells and suppression of IFNα dramatically reduced IFITM1, PLSCR1, p-STAT1, and p-STAT2 expression in the resistant cells. Lastly, neutralizing antibody against IFNAR1/2 and knockdown of STAT1/STAT2 completely suppressed IFITM1, PLSCR1, p-STAT1, and p-STAT2 expression in the resistant cells, thus confirming the involvement of the canonical IFNα signaling pathway in driving the overexpression of IFITM1 and other interferon-stimulated genes (ISGs) in the resistant cells.ConclusionOverall, these results demonstrate that constitutive overexpression of ISGs enhances the progression of AI-resistant breast cancer and that suppression of IFITM1 and other ISGs sensitizes AI-resistant cells to estrogen-induced cell death.Electronic supplementary materialThe online version of this article (doi:10.1186/s13058-014-0506-7) contains supplementary material, which is available to authorized users.
机译:简介目前,使用芳香酶抑制剂(AIs)去除雌激素是绝经后患有激素受体阳性乳腺癌的妇女的标准护理。不幸的是,大多数接受AIs治疗的患者最终会产生耐药性,不可避免地导致患者复发,并最终导致死亡。产生抗药性的机制仍不完全清楚,但是,最近的研究表明,干扰素信号传导受损/有缺陷可能发挥了作用。在本研究中,我们评估了IFITM1和PLSCR1的功能作用。方法采用实时荧光定量PCR和Western印迹法评估AI耐药的MCF-7:5C乳腺癌中IFITM1,PLSCR1,STAT1,STAT2和IRF-7的mRNA和蛋白水平。癌细胞以及AI敏感的MCF-7和T47D细胞。免疫组织化学(IHC)染色是在由正常乳腺组织,原发性乳腺肿瘤和AI耐药复发性肿瘤组成的组织微阵列上进行的。酶联免疫吸附测定用于定量细胞内IFNα水平。中和抗体被用来阻断1型干扰素受体IFNAR1的信号传导。使用小干扰RNA(siRNA)敲低IFITM1,PLSCR1,STAT1,STAT2,IRF-7和IFNα表达。结果我们发现IFITM1和PLSCR1在抗AI的MCF-7:5C乳腺癌细胞和AI-耐药性肿瘤以及IFITM1的siRNA抑制显着抑制了耐药性细胞增殖,迁移和侵袭的能力。有趣的是,抑制IFITM1可以显着增强抗AI的MCF-7:5C细胞中雌二醇诱导的细胞死亡,并显着增加这些细胞中p21,Bax和Noxa的表达。与亲本MCF-7细胞相比,在AI耐药MCF-7:5C细胞中检测到IFNα的水平显着升高,并且抑制IFNα显着降低了耐药细胞中IFITM1,PLSCR1,p-STAT1和p-STAT2的表达。最后,针对IFNAR1 / 2的中和抗体和STAT1 / STAT2的敲低完全抑制了耐药细胞中IFITM1,PLSCR1,p-STAT1和p-STAT2的表达,从而证实了典型的IFNα信号通路参与了IFITM1的过表达结论总的来说,这些结果表明,ISG的组成型过表达促进了AI耐药乳腺癌的进展,而对IFITM1和其他ISG的抑制则使AI耐药细胞对雌激素诱导的细胞敏感。电子补充材料本文的在线版本(doi:10.1186 / s13058-014-0506-7)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号